Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Treasury Shares (2023 - 2025)

Historic Treasury Shares for 60 Degrees Pharmaceuticals (SXTP) over the last 3 years, with Q3 2025 value amounting to $7.6 million.

  • 60 Degrees Pharmaceuticals' Treasury Shares fell 2255.86% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year decrease of 2255.86%. This contributed to the annual value of $1.8 million for FY2024, which is 324692.91% up from last year.
  • Latest data reveals that 60 Degrees Pharmaceuticals reported Treasury Shares of $7.6 million as of Q3 2025, which was down 2255.86% from $2.1 million recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' Treasury Shares' 5-year high stood at $9.8 million during Q3 2024, with a 5-year trough of $52737.0 in Q4 2023.
  • Over the past 3 years, 60 Degrees Pharmaceuticals' median Treasury Shares value was $1.3 million (recorded in 2024), while the average stood at $2.5 million.
  • Over the last 5 years, 60 Degrees Pharmaceuticals' Treasury Shares had its largest YoY gain of 361610.98% in 2024, and its largest YoY loss of 5630.4% in 2024.
  • Quarter analysis of 3 years shows 60 Degrees Pharmaceuticals' Treasury Shares stood at $52737.0 in 2023, then soared by 3246.93% to $1.8 million in 2024, then soared by 329.87% to $7.6 million in 2025.
  • Its Treasury Shares stands at $7.6 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.1 million for Q1 2025.